홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Acetic Acid → HCID 89691222, 화합물

HRID 1504026
노트
인쇄 미리보기

반응식

HRID 1504026 반응식
Cl.N[CH:3]1[CH2:8][CH2:7][CH:6]([O:9][C:10]2[C:11]3[C:12]4[CH2:13][C@H:14]([CH2:23][C:24]([NH2:26])=[O:25])[CH2:15][CH2:16][C:17]=4[S:18][C:19]=3[N:20]=[CH:21][N:22]=2)[CH2:5][CH2:4]1.C=O.[CH3:29]C(O)=O.[BH3-][C:34]#[N:35].[Na+]>CO>[CH3:29][N:35]([CH3:34])[CH:3]1[CH2:8][CH2:7][CH:6]([O:9][C:10]2[C:11]3[C:12]4[CH2:13][C@H:14]([CH2:23][C:24]([NH2:26])=[O:25])[CH2:15][CH2:16][C:17]=4[S:18][C:19]=3[N:20]=[CH:21][N:22]=2)[CH2:5][CH2:4]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 4

HCID 176Acetic AcidHCID 712FormaldehydeHCID 5003444Sodium cyanoborohydrideHCID 86695181HCID 86695181, 화합물

생성물 1

HCID 89691222HCID 89691222, 화합물

시약·촉매·용매 1

HCID 887Methanol용매

실험 절차

A solution of tert-butyl N-(4-[[(12R)-12-(carbamoylmethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (72 mg, 0.16 mmol, 1.00 equiv) in 5 mL of dichloromethane (5 mL) was added 6 M aqueous hydrochloric acid (0.5 mL) at 0° C. and the resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum to give 62 mg (crude) of 2-[(12R)-3-[(4-aminocyclohexyl)oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide hydrochloride as a yellow solid. The crude hydrochloride in 4 mL of MeOH was added HCHO (37%, 1 mL) and 0.5 mL of HOAc at room temperature. Then NaCNBH3 (31 mg, 0.49 mmol, 2.54 equiv) was added and the resulting solution was stirred for 4 h at ambient temperature. The resulting mixture was filtered through a thin silica column and further purified by preparative HPLC under the following conditions (Waters): column: Xbridge Prep C18 5 um, 19*150 mm; mobile phase: water with 0.05% NH4HCO3 and CH3CN (5.0% CH3CN up to 41.0% in 9 min, up to 95.0% in 2 min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV detection at 220/254 nm. The product-containing fractions were collected and evaporated under reduced pressure to give the desired 2-[(12R)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide (13.8 mg) as a white solid. MS: 389 (M+H)+. 1H NMR (300 MHz, CDCl3): δ 8.51 (s, 1H), 5.46-5.40 (m, 1H), 5.24-5.21 (m, 1H), 3.30-3.24 (m, 1H), 2.91 (m, 2H), 2.62-2.59 (m, 1H), 2.56-2.32 (m, 11H), 2.15-2.11 (m, 1H), 2.02-2.00 (m, 3H), 1.74-1.49 (m, 6H).

후처리

  1. filtrationThe resulting mixture was filtered through a thin silica column
  2. customfurther purified by preparative HPLC under the following conditions (Waters)
  3. waitmobile phase: water with 0.05% NH4HCO3 and CH3CN (5.0% CH3CN up to 41.0% in 9 min
  4. waitup to 95.0% in 2 min
  5. waitdown to 5.0% in 2 min)
  6. customThe product-containing fractions were collected
  7. customevaporated under reduced pressure

출처 및 근거

ORD 기록
ord-59fab8c84b7843a8ac8a10711c7a8f92
출처 데이터셋
uspto-grants-2015_12
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US09212190B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트